Your account is not claimed yet. You can sign up with ORCID to claim your account.

Ilva Dana Rupenthal (Ilva D Rupenthal)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 29

Top Venues

International journal of molecular sciences

Pharmaceutical development and technology

Cell biology international

Molecular pharmaceutics

The University of Auckland

University of Auckland (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

The University of Auckland Feb 1o 2019

New Zealand

Associate Professor and Director of the Buchanan Ocular Therapeutics Unit (Ophthalmology) :: Ophthalmology

Education History

University of Auckland

New Zealand

PHD :: Pharmacy

Publications

Odunayo Omolola Mugisho, Jyoti Aryal, Avik Shorne, Heather Lyon, Monica L Acosta, Colin R Green, Ilva Dana Rupenthal
Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy. International journal of molecular sciences 24 (4) (2023)
Odunayo Omolola Mugisho, Jyoti Aryal, Avik Shorne, Heather Lyon, Monica L Acosta, Colin R Green, Ilva Dana Rupenthal
Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy. International journal of molecular sciences 24 (4) (2023)
Odunayo Omolola Mugisho, Jyoti Aryal, Avik Shorne, Heather Lyon, Monica L Acosta, Colin R Green, Ilva Dana Rupenthal
Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy. International journal of molecular sciences 24 (4) (2023)
Odunayo Omolola Mugisho, Jyoti Aryal, Avik Shorne, Heather Lyon, Monica L Acosta, Colin R Green, Ilva Dana Rupenthal
Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy. International journal of molecular sciences 24 (4) (2023)
Dian Zhuang, Stuti L Misra, Odunayo Omolola Mugisho, Ilva Dana Rupenthal, Jennifer P Craig
NLRP3 Inflammasome as a Potential Therapeutic Target in Dry Eye Disease. International journal of molecular sciences 24 (13) (2023)
Odunayo Omolola Mugisho, Jyoti Aryal, Avik Shorne, Heather Lyon, Monica L Acosta, Colin R Green, Ilva Dana Rupenthal
Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy. International journal of molecular sciences 24 (4) (2023)
Odunayo Omolola Mugisho, Jyoti Aryal, Avik Shorne, Heather Lyon, Monica L Acosta, Colin R Green, Ilva Dana Rupenthal
Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy. International journal of molecular sciences 24 (4) (2023)
Avik Shome, Odunayo O Mugisho, Rachael Louise Niederer, Ilva Dana Rupenthal
Comprehensive Grading System for Experimental Autoimmune Uveitis in Mice. Biomedicines 11 (7) (2023)
Ilva Dana Rupenthal, Priyanka Agarwal, Benedict B Uy, Jaeun Kim, Angela A Cunningham, Ali Seyfoddin, Simon Swift, Jennifer P Craig
Preparation and Characterisation of a Cyclodextrin-Complexed Mānuka Honey Microemulsion for Eyelid Application. Pharmaceutics 14 (7) (2022)
Charisse Y-J Kuo, Jack J Maran, Emma G Jamieson, Ilva Dana Rupenthal, Rinki Murphy, Odunayo O Mugisho
Characterization of NLRP3 Inflammasome Activation in the Onset of Diabetic Retinopathy. International journal of molecular sciences 23 (22) (2022)
Henry H Louie, Odunayo O Mugisho, Lawrence W Chamley, Ilva Dana Rupenthal
Extracellular Vesicles as Biomarkers and Therapeutics for Inflammatory Eye Diseases. Molecular pharmaceutics (2022)
Priyanka Agarwal, Jennifer P Craig, Ilva Dana Rupenthal
Formulation Considerations for the Management of Dry Eye Disease. Pharmaceutics 13 (2) (2021)
Priyanka Agarwal, Sairam Behera, Ilva Dana Rupenthal
Ocular Distribution of Papaverine Using Non-aqueous Vehicles. AAPS PharmSciTech 22 (5) (2021)
Heather Kang, Naibo Yin, Heather Lyon, Ilva Dana Rupenthal, Sachin S Thakur, Odunayo Omolola Mugisho
The influence of hyperglycemia on the safety of ultrasound in retinal pigment epithelial cells. Cell biology international 45 (3) (2021)
Heather Lyon, Naibo Yin, Ilva Dana Rupenthal, Colin R Green, Odunayo Omolola Mugisho
Blocking connexin43 hemichannels prevents TGF-β2 upregulation and epithelial-mesenchymal transition in retinal pigment epithelial cells. Cell biology international (2021)
Sachin S Thakur, Arian Bai, Doris Chan, Jonathan Lu, Marie Lu, Aimee Su, Janesha Perera, Simon Swift, Darren Svirskis, Ilva Dana Rupenthal
Ex vivo evaluation of the influence of pH on the ophthalmic safety, antibacterial efficacy and storage stability of povidone-iodine. Clinical & experimental optometry 104 (2) (2021)
Mohd N Mat Nor, Ilva Dana Rupenthal, Colin R Green, Monica L Acosta
Differential Action of Connexin Hemichannel and Pannexin Channel Therapeutics for Potential Treatment of Retinal Diseases. International journal of molecular sciences 22 (4) (2021)
Heather Lyon, Avik Shome, Ilva Dana Rupenthal, Colin R Green, Odunayo O Mugisho
Tonabersat Inhibits Connexin43 Hemichannel Opening and Inflammasome Activation in an In Vitro Retinal Epithelial Cell Model of Diabetic Retinopathy. International journal of molecular sciences 22 (1) (2020)
Mohammad Mehdi Mahboobian, Ali Seyfoddin, Reza Aboofazeli, Seyed Mohsen Foroutan, Ilva Dana Rupenthal
Brinzolamide-loaded nanoemulsions: ex vivo transcorneal permeation, cell viability and ocular irritation tests. Pharmaceutical development and technology 24 (5) (2019)
Odunayo Omolola Mugisho, Ilva Dana Rupenthal, François Paquet-Durand, Monica L Acosta, Colin R Green
Targeting connexin hemichannels to control the inflammasome: the correlation between connexin43 and NLRP3 expression in chronic eye disease. Expert opinion on therapeutic targets 23 (10) (2019)
Odunayo O Mugisho, Ilva Dana Rupenthal, David M Squirrell, Sarah J Bould, Helen V Danesh-Meyer, Jie Zhang, Colin R Green, Monica L Acosta
Intravitreal pro-inflammatory cytokines in non-obese diabetic mice: Modelling signs of diabetic retinopathy. PloS one 13 (8) (2018)
Frazer P Coutinho, Colin R Green, Ilva Dana Rupenthal
Intracellular oligonucleotide delivery using the cell penetrating peptide Xentry. Scientific reports 8 (1) (2018)
Odunayo O Mugisho, Colin R Green, David M Squirrell, Sarah Bould, Helen V Danesh-Meyer, Jie Zhang, Monica L Acosta, Ilva Dana Rupenthal
Connexin43 hemichannel block protects against the development of diabetic retinopathy signs in a mouse model of the disease. Journal of molecular medicine (Berlin, Germany) 97 (2) (2018)
Odunayo O Mugisho, Colin R Green, Jie Zhang, Nicolette Binz, Monica L Acosta, Elizabeth Rakoczy, Ilva Dana Rupenthal
Immunohistochemical Characterization of Connexin43 Expression in a Mouse Model of Diabetic Retinopathy and in Human Donor Retinas. International journal of molecular sciences 18 (12) (2017)
Sachin S Thakur, Jared Solloway, Anneloes Stikkelman, Ali Seyfoddin, Ilva Dana Rupenthal
Phase transition of a microemulsion upon addition of cyclodextrin - applications in drug delivery. Pharmaceutical development and technology 23 (2) (2017)
Rohit Bisht, Abhirup Mandal, Jagdish K Jaiswal, Ilva Dana Rupenthal
Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 10 (2) (2017)
Ghada Zidan, Ilva Dana Rupenthal, Carol Greene, Ali Seyfoddin
Medicated ocular bandages and corneal health: potential excipients and active pharmaceutical ingredients. Pharmaceutical development and technology 23 (3) (2017)
Di Huang, Ying-Shan Chen, Ilva Dana Rupenthal
Hyaluronic Acid Coated Albumin Nanoparticles for Targeted Peptide Delivery to the Retina. Molecular pharmaceutics 14 (2) (2017)
Rohit Bisht, Ilva Dana Rupenthal
PLGA nanoparticles for intravitreal peptide delivery: statistical optimization, characterization and toxicity evaluation. Pharmaceutical development and technology 23 (4) (2016)

Ilva Dana Rupenthal.css-eqlu8i{font-size:small;padding-left:4px;} (Ilva D Rupenthal)

Publication Activity (10 Years)

Top Topics

Top Venues

Ilva Dana Rupenthal (Ilva D Rupenthal)